SUNNYVALE, California,
July 21, 2016 /PRNewswire/ --
Accuray Incorporated (NASDAQ: ARAY) announced today preliminary
results from a prospective, phase II trial evaluating once-daily
accelerated partial breast irradiation (APBI) in patients treated
with the TomoTherapy® System. The study, published in the June
issue of the peer-reviewed AntiCancer Research, International
Journal of Cancer Research and Treatment, reported no
recurrence of cancer in the treated breast at median follow-up of
34 months. Additionally, more than 95 percent of patients and their
physicians rated cosmesis -- preservation of the normal appearance
of the breast -- as good/excellent.
(Logo:
http://photos.prnewswire.com/prnh/20151126/291246LOGO )
(Photo:
http://photos.prnewswire.com/prnh/20160721/391950 )
"The phase II trial results are very encouraging for a carefully
selected patient population, and should be considered by all
radiation oncologists when evaluating APBI treatments for their
low-risk patients," said Prof. Ugo De
Paula, Department of Radiation Oncology, San
Giovanni-Addolorata Hospital, Rome-Italy. "In our experience we found there
was extremely good patient compliance with their APBI treatment
regimen because of a very short, 10-day schedule and well-tolerated
treatments. We believe that using daily image guidance, which is
unique to the TomoTherapy System, is essential for the precise
identification of the tumor bed and reproducibility of
treatment."
The study titled, "Once Daily Accelerated Partial Breast
Irradiation: Preliminary Results with Helical TomoTherapy,"
provides results for 111 patients treated with APBI following
lumpectomy. It also demonstrated that:
- Delivering the dose once a day over 10 days (others studies use
10 fractions twice-daily) could be a contributing factor to better
cosmetic outcomes and lower toxicity. This is made possible because
of the integrated image guidance of the TomoTherapy System and its
excellent dose homogeneity;
- Patient compliance was remarkable as all patients completed the
treatment without interruption;
- Treatments were very well tolerated with minimal acute or late
side effects.
"The TomoTherapy System is proving itself to be an excellent
breast radiotherapy device. In fact, some sites have purchased the
system to use solely for breast radiotherapy," said Fabienne
Hirigoyenberry-Lanson, PhD, vice president medical affairs, at
Accuray. "Studies such as the one undertaken by Dr. de Paula and
his colleagues reinforce the benefits which the TomoTherapy System
can provide and highlight why customers worldwide rely on the
system as their mainstream radiation treatment device."
The TomoTherapy System is the only radiation system specifically
designed for image-guided intensity-modulated radiation therapy
(IMRT). Leveraging a CT scanner-based platform, TomoHelical™ mode
enables continuous delivery from 360 degrees around the patient
with highly conformal and homogeneous dose to the tumor. A
clinician can also choose to deliver treatment from specific fixed
angles via TomoDirect™ mode. These unique features, combined with
daily 3D image guidance, enable physicians to efficiently deliver
highly accurate, individualized dose distributions which precisely
conform to the shape of the patient's tumor while minimizing dose
to normal, healthy tissue for a variety of cancer types, including
breast cancer. This is especially important for women diagnosed
with cancer in the left breast, where the tumor may be close to
critical organs such as the heart.
For further information on the TomoTherapy System, visit
http://www.accuray.com/solutions/treatment-delivery/tomotherapy-treatment-delivery/h-series
About the Phase II Trial
The study was designed to assess the role of once-daily
accelerated partial breast irradiation in terms of cosmetic and
local results. The primary endpoints of this trial were breast
tumor recurrence and toxicity. Secondary outcomes were rates of
adverse cosmesis, quality of life and compliance. Patients who had
previously undergone breast-conserving surgery were enrolled in the
study. Radiation treatments were administered in 10 daily fractions
of 3.85 Gy.
Important Safety Information
For Important Safety Information please refer to
http://www.accuray.com/safety-statement-radiation-treatment
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology
company that develops, manufactures and sells precise, innovative
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit http://www.accuray.com .
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient outcomes and Accuray's leadership
position in radiation oncology innovation and technologies.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from
expectations, including but not limited to the risks detailed from
time to time under the heading "Risk Factors" in the company's
report on Form 10-K, filed on August 28,
2015, the company's reports on Form 10-Q, filed on
November 5, 2015 and February 1, 2016 and April
29, 2016, and the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on
any forward-looking statements.